Daily Biotech Pulse: VistaGen’s Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal’s Lead Asset
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: VistaGen Therapeutics Inc VTGN has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for…
Quest Diagnostics (DGX) Q2 Earnings
[ad_1] Quest Diagnostics Inc DGX posted a better-than-expected Q2 FY22 adjusted EPS of $2.36, though down 25.8% Y/Y, beating the consensus of $2.20. Sales came in at $2.45 billion, a…